When FDA cleared, OcuFLOW’s product will be inexpensive, noninvasive and will measure the ocular blood flow in each eye in less than 15 seconds.  It will be the only technology capable of quantitatively measuring composite pulsatile blood flow within the eye including both choroidal blood flow (90%) and retinal blood flow (10%). Other technologies measure only the retinal blood flow which is 10% of blood flow within the eye. The OcuFLOW-COBFA is the only current technology for measuring ocular blood flow based on scientific principles with 40 years of validation.